Picture: Roche

Genentech: New Head of Research and Early Development

Aviv Regev will follow Michael Varney as Head of Genentech Research and Early Development (gRED) at Roche subsidiary Genentech. Varney will retire from the company at the end of July.

Aviv Regev, currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator of the Howard Hughes Medical Institute, will join Genentech as the new Head of gRED and will become a member of the enlarged Corporate Executive Committee as of 1 August 2020. She will be based in South San Francisco.

In particular, Regev has pioneered assays for RNA sequencing in single-cells, machine learning algorithms for distilling biological knowledge from the resulting information, and many of the first demonstrations of how to yield foundational new insights into an extraordinarily wide range of molecular circuits, systems, and fields, including immunology, neurobiology, development, inflammatory disease, cancer, and evolution. In doing so, her work is helping to answer the most general of biological questions - how cells and their circuits function and rewire, and how these dynamics underlie health and malfunction in disease.

Aviv Regev has a Ph.D. in computational biology and Master of Science from Tel Aviv University.  Through her pioneering efforts she is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease.